home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  March 21, 2018
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 583 active entries

Vybion, Inc.

33 Thornwood Dr.
Ithaca, NY 14850
United States of America, New York

Phone: 607-266-0860
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Vybion uses proprietary technologies to validate drug targets and develop therapeutic drugs for unmet needs.  INT41, an Intrabody disease modifying drug delivered as a Gene Therapy for the treatment of Huntington's disease (HD) a lethal neurodegenerative disease.   INT41 prevents oligomer and aggregate formation of mutant Huntingtin protein and gene dysregulation. Both cell-based and animal models have demonstrated efficacy and mechanism of action.  Other Intrabody programs are directed at precise targeting of protein-protein interactions coupled with gene expression profiling to identify and validate drug targets for subsequent small molecule discovery. 

Selected Categories:

Product Company   Service Company
- General

Last update of this entry: March 10, 2015

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.